<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Nanomedicine (Lond)</journal-id>
<journal-id journal-id-type="iso-abbrev">Nanomedicine (Lond)</journal-id>
<journal-id journal-id-type="publisher-id">NNM</journal-id>
<journal-title-group>
<journal-title>Nanomedicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1743-5889</issn>
<issn pub-type="epub">1748-6963</issn>
<publisher>
<publisher-name>Future Medicine Ltd</publisher-name>
<publisher-loc>London, UK</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31038003</article-id>
<article-id pub-id-type="pmc">6613044</article-id>
<article-id pub-id-type="doi">10.2217/nnm-2019-0059</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Dodecyl creatine ester-loaded nanoemulsion as a promising therapy for creatine transporter deficiency</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ullio-Gamboa</surname>
<given-names>Gabriela</given-names>
</name>
<xref ref-type="aff" rid="AFF1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Udobi</surname>
<given-names>Kenea C</given-names>
</name>
<xref ref-type="aff" rid="AFF2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dezard</surname>
<given-names>Sophie</given-names>
</name>
<xref ref-type="aff" rid="AFF3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Perna</surname>
<given-names>Marla K</given-names>
</name>
<xref ref-type="aff" rid="AFF2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miles</surname>
<given-names>Keila N</given-names>
</name>
<xref ref-type="aff" rid="AFF2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Costa</surname>
<given-names>Narciso</given-names>
</name>
<xref ref-type="aff" rid="AFF1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taran</surname>
<given-names>Frédéric</given-names>
</name>
<xref ref-type="aff" rid="AFF3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pruvost</surname>
<given-names>Alain</given-names>
</name>
<xref ref-type="aff" rid="AFF4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Benoit</surname>
<given-names>Jean-Pierre</given-names>
</name>
<xref ref-type="aff" rid="AFF5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Skelton</surname>
<given-names>Matthew R</given-names>
</name>
<xref ref-type="aff" rid="AFF2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>de Lonlay</surname>
<given-names>Pascale</given-names>
</name>
<xref ref-type="aff" rid="AFF6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mabondzo</surname>
<given-names>Aloïse</given-names>
</name>
<xref ref-type="corresp" rid="COR1">*</xref>
<xref ref-type="aff" rid="AFF1">
<sup>1</sup>
</xref>
</contrib>
<aff id="AFF1"><label>1</label>Service de Pharmacologie et d’Immunoanalyse, CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France</aff>
<aff id="AFF2"><label>2</label>Department of Pediatrics, University of Cincinnati College of Medicine &amp; Division of Neurology, Cincinnati Children’s Research Foundation, Cincinnati, OH, USA</aff>
<aff id="AFF3"><label>3</label>Service de Chimie Bio Organique et de Marquage CEA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France</aff>
<aff id="AFF4"><label>4</label>Service de Pharmacologie et d’Immunoanalyse (SPI), Plateforme Smart-MS, CEA, INRA, Université Paris-Saclay, F-91191 Gif-sur-Yvette, France</aff>
<aff id="AFF5"><label>5</label>LUNAM Université-Micro et Nanomédecines Biomimétiques, F-49933 Angers, France, INSERM U1066, IBS-CHU, 4 rue Larrey, F-49933 Angers Cedex 9, France</aff>
<aff id="AFF6"><label>6</label>Centre de Référence des Maladies Héréditaires du Métabolisme de l’Enfant et de l’Adulte, Hôpital Necker-Enfants Malades, APHP, Université Paris Descartes, Imagine, INEM, Filière G2M, metabERN, Paris, France</aff>
</contrib-group>
<author-notes>
<corresp id="COR1"><label>*</label>Author for correspondence: Tel.: <phone>+33 1 69081321</phone>; <email xlink:href="mailto:aloise.mabondzo@cea.fr">aloise.mabondzo@cea.fr</email></corresp>
<fn fn-type="COI-statement">
<p>
<bold>Financial &amp; competing interests disclosure</bold>
</p>
<p>This work was supported by Fondation Le Jeune, Lucane Pharma and X-traordinaire (which is a patient group dedicated to intellectual deficiency rare diseases. Additional funding to MRS was provided by NIH (grant number: HD080910). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.</p>
<p>No writing assistance was utilized in the production of this manuscript.</p>
</fn>
</author-notes>
<pub-date date-type="pub" publication-format="electronic">
<day>30</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date date-type="pub" publication-format="print">
<month>6</month>
<year>2019</year>
</pub-date>
<volume>14</volume>
<issue>12</issue>
<fpage>1579</fpage>
<lpage>1593</lpage>
<history>
<date date-type="received">
<day>07</day>
<month>2</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>3</month>
<year>2019</year>
</date>
<date date-type="online">
<day>30</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 Future Medicine Ltd</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="nnm-14-1579.pdf" xlink:title="pdf"></self-uri>
<abstract>
<p>Creatine transporter (CrT) deficiency is an X-linked intellectual disability caused by mutations of CrT.</p>
<sec>
<title>Aim:</title>
<p>This work focus on the preclinical development of a new therapeutic approach based on a microemulsion (ME) as drug delivery system for dodecyl creatine ester (DCE).</p>
</sec>
<sec>
<title>Materials &amp; methods:</title>
<p>DCE-ME was prepared by titration method. Novel object recognition (NOR) tests were performed before and after DCE-ME treatment on <italic>Slc6a8<sup>-/y</sup></italic> mice.</p>
</sec>
<sec>
<title>Results:</title>
<p>Intranasal administration with DCE-ME improved NOR performance in <italic>Slc6a8<sup>-/y</sup></italic> mice. <italic>Slc6a8<sup>-/y</sup></italic> mice treated with DCE-ME had increased striatal ATP levels mainly in the striatum compared with vehicle-treated <italic>Slc6a8<sup>-/y</sup></italic> mice which was associated with increased expression of synaptic markers.</p>
</sec>
<sec>
<title>Conclusion:</title>
<p>These results highlight the potential value of DCE-ME as promising therapy for creatine transporter deficiency.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>creatine</kwd>
<kwd>creatine transporter deficiency</kwd>
<kwd>dodecyl creatine ester</kwd>
<kwd>drug delivery</kwd>
<kwd>microemulsion</kwd>
<kwd>nasal administration</kwd>
<kwd>neurotherapeutics for CTD</kwd>
</kwd-group>
<counts>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>